PHVS · Pharvaris N.V.
Market Cap
$2.25B
Shares
70.20M
Volume · Oct 5
816.23K
Avg daily vol (3M)
744.19K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$30.49
Open$31.19
Day$30.15–31.47
52W close$20.96–38.86
Avg vol 30d958K
Short int1.8M · 2.5% float · 1.2d
Short vol48%
DataFeb 2021–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$56.57M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.9%
Year over year · more shares
Price change (1Y)
+34.6%
Trailing year
Short interest
2.5%
Latest settlement · 1.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
−13%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
53%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
+6%
trailing
YTD return
+10%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $35 › 200d $30 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$16.2M over 90 days · 100% sells
Short interest
Falling
2.54% of float · ▼ -17.4% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
125 holders — near 3-yr high, broad support
Squeeze score
38
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
55%
annualized · 1-yr
Max drawdown
−22%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
−13%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
53%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $35 › 200d $30 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$16.2M over 90 days · 100% sells
Short interest
Falling
2.54% of float · ▼ -17.4% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
125 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $21
Now $30 · 53%
Range high $39
vs 200-day avg +0%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHVS
this stock
Pharvaris N.V.
|
$2.25B | +9.9% | — | — | 2.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHVS | -4.5% | -13.5% | +6.3% | -3.9% | +9.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -5.7% | -14.1% | -5.3% | -5.5% | -3.8% |